reference/22998847

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22998847

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
issn	1664-2392
pageRange	35-
publicationName	Frontiers in Endocrinology
startingPage	35
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_f223bba39021accee0f7a57ffd95ef6d http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a1ebfe17b0713ecaf89801f0370c078d http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_fd70cd3add3d404b48510de552ba4387
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_c0ed422bb43f19254987cf945ae517d8 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_727754750fce599daa9dfad240aa0fd3
bibliographicCitation	Michmerhuizen AR, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Liu M, Pesch AM, Zhang A, Ritter C, Ward ST, Santola A, Nyati S, Rae JM, Hayes D, Feng FY, Spratt D, Wahl D, Eisner J, Pierce LJ, Speers C. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Front Endocrinol (Lausanne). 2020;11():35. PMID: 32117061; PMCID: PMC7027396.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f52d587ba619f1c73882541938a6234f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e154f5682972391a4230f1a846a766a1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_800340728912e649a75e5c3165451e19 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9688d1cb5c4659746b52dd7fe9463d7a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8368a17e2df37805b7992c647b094465 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f077babc9b7441e5ba208e761d62705 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e6b73fdffd52f62ae843a7570d577496 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-6963-9468 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fcd5f93d9403f8a2c6813e65cd093e86 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a2e0979cfc5267c132f8b5a0e6e5710e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5fbcbb834234997888a9a82612422549 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_892c8f62c595474f29cd42dee83e4e18 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_380597a06356f26389772b881ac0988e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3cced5821cda53fdab552a2c06c3d196 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5179c6fa4d3bd2d737fb84f0bb5dc90b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_36806469a29bb825ffb6d748e4970fe7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bf7994a5be025624def725ba37c4916c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c48f0f9cf07a2e92a928359ffabcaec http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f12330ff885d52209708ae27c522fed3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63386b16cfdba7b1f8fd282e3eece89d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2103179c8d6f889054d2a286dcf0d3c7
date	2020-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/32117061 https://pubmed.ncbi.nlm.nih.gov/PMC7027396 https://doi.org/10.3389/fendo.2020.00035
isPartOf	https://portal.issn.org/resource/ISSN/1664-2392 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39155
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
discusses	http://id.nlm.nih.gov/mesh/M0007520 http://id.nlm.nih.gov/mesh/M0012769 http://id.nlm.nih.gov/mesh/M0020523 http://id.nlm.nih.gov/mesh/M0016576 http://id.nlm.nih.gov/mesh/M0018388 http://id.nlm.nih.gov/mesh/M000743732 http://id.nlm.nih.gov/mesh/M0577955 http://id.nlm.nih.gov/mesh/M0366130 http://id.nlm.nih.gov/mesh/M0014459 http://id.nlm.nih.gov/mesh/M0014878 http://id.nlm.nih.gov/mesh/M0545741 http://id.nlm.nih.gov/mesh/M0002327 http://id.nlm.nih.gov/mesh/M0021911 http://id.nlm.nih.gov/mesh/M0018556
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D064726Q000532 http://id.nlm.nih.gov/mesh/D059002Q000494 http://id.nlm.nih.gov/mesh/D013254Q000037 http://id.nlm.nih.gov/mesh/D004791Q000494 http://id.nlm.nih.gov/mesh/D009281Q000494 http://id.nlm.nih.gov/mesh/D011838Q000494 http://id.nlm.nih.gov/mesh/D014230Q000494
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D009570 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D064726Q000235 http://id.nlm.nih.gov/mesh/D016513 http://id.nlm.nih.gov/mesh/D051379 http://id.nlm.nih.gov/mesh/D010669Q000031 http://id.nlm.nih.gov/mesh/D061986 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008810 http://id.nlm.nih.gov/mesh/D011944Q000235 http://id.nlm.nih.gov/mesh/D045744 http://id.nlm.nih.gov/mesh/D064726Q000473 http://id.nlm.nih.gov/mesh/D011944Q000378 http://id.nlm.nih.gov/mesh/D064726Q000188 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D001549 http://id.nlm.nih.gov/mesh/D008190Q000037 http://id.nlm.nih.gov/mesh/D011836Q000187 http://id.nlm.nih.gov/mesh/D023041 http://id.nlm.nih.gov/mesh/D010669Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID78357816 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8937 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9c2eb41267934654ad86d8795624a05b http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_005ef34c8ba989d84eb20cdc3a19dd7c http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_c582dec943ff7b743aa0691df291cea6 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID15951529 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11451

Total number of triples: 93.